【摘要】 目的观察氯吡格雷联合低分子肝素治疗进展性缺血性脑卒中的临床疗效和安全性。方法 60例急性进展性缺血性脑卒中患者被分为治疗组和对照组,每组各30例。入院后均在常规应用灯盏细辛素注射液、神经营养剂、尼莫地平、辛伐他汀和通心络治疗的基础上,对照组患者加用阿司匹林 150mg,1次／d;治疗组加用氯吡格雷75mg,1次／d,低分子肝素6150IU,腹部皮下注射,2次／d,连续治疗10d。治疗前及治疗后14d,对两组患者的血小板、凝血酶原时间和活化部分凝血活酶时间及神经功能缺损评分进行评定。结果治疗组患者治疗后神经功能缺损评分为(9．63±3．27)分,对照组(12.43±3．45) 分,两组间比较差异具有显著性意义(P<0．05)。两组患者血小板、凝血酶原时间和活化部分凝血酶原时间测定值均在正常值范围内,组间比较差异无显著性意义。两组无一例出现明显不良反应。结论氯吡格雷联合低分子肝素治疗进展性缺血性脑卒中疗效确切,安全可靠。更多还原

【Abstract】 Objective To observe the clinical curative effect and safety of clopidogrel combined with low molecular heparin in the treatment of patients with progressive ischemic stroke. Methods Sixty patients with acute progressive ischemic stroke were randomly divided into treatment and control group, each of 30 cases. Patients in both groups were treated routinely with breviscapine, neurotrophic agents, nimodipine, sim-vastatin and tongxinluo after admission, while the patients in control group were administered aspirin (150 mg) once daily for 10d, but patients in treatment group were administered clopidogrel (75 mg) once daily and low molecular heparin (6 150IU, iH) twice daily for 10d. Platelet number, prothrombin time (PT), active partial prothrombin time (APTT), neurological deficit scale (NDS) were evaluated in every patient before and 14 d after administration of drugs. Results After treatment the NDS of patients in treatment group was (9.63±3.27), while that in control group was (12.43±3.45), there was significant difference between two groups (P<0.05). The platelet count, PT and APTT of patients in both groups were within normal limits without significant difference between two groups. None of obvious adverse effect was found. Conclusion The curative effect of combined clopidogrel and low molecular heparin in treatment of patients with progressive ischemic stroke is definite, safe and reliable.更多还原